00:00The commitment of MSD to counter the lung tumor is a commitment at 360 degrees, which starts
00:12from a research that has meant for the entire scientific community a revolution in the paradigm
00:19of care, and we are talking about immuno-oncology.
00:23Speaking of the lung tumor, there have been several studies aimed at capturing the possible
00:30nuances, the possible differences from patient to patient, and the type of tumor itself.
00:36And this is why the research has not stopped with respect to the first indication related
00:42to the study of Kynote 189, but has gone on with ever more encouraging news and more
00:48life and quality of life for many more patients.
00:52And this is why our country must be conducive to innovation, as we say, it must stimulate
01:00that innovation and that research so that it can bring more and more answers to the many
01:05patients who, unfortunately, have to go against this important health problem.
01:11And this is why, on our part as MSD, we are not tired of researching and investing heavily
01:18in research.
01:19We are the first biopharmaceutical company in the world for research intensity, 42% of
01:25our revenue, which means more than 30 billion dollars of research invested in research and
01:31development, which also equate to our 105 million euros, which are very important as
01:38they are compared to a total of 700 million euros invested in research and development
01:42by the entire pharmaceutical sector in Italy.
01:46As a company on its own, we really invest a lot.
01:49What does this mean?
01:51It means, as an innovation, access to innovation immediately for patients and, above all,
01:57opportunities to really be included in what is the great engine of research.
02:03The position of MSD and the opinion of MSD with respect to the balance sheet is certainly
02:08generally favorable because we continue to go in the right direction, that is, the increase
02:13of the national health fund.
02:16This increase responds to many needs, which are important needs, because unfortunately
02:22Italy, despite the recent increases in the national health fund, is far behind in terms
02:28of health investment per individual citizen compared to other countries such as France,
02:34Spain, Germany, and so on.
02:36As regards, in particular, the fund of innovative pharmaceuticals, we have welcomed with great
02:43favor the good news of the desire to include also the conditioned innovativeness and also
02:49the reserve antibiotics, which are certainly also another of the pillars of the research
02:54towards which we invest in an important way.
02:57However, it can certainly be perfected because, as often happens, there are particular rules
03:05that go to vanish the great effort that is wanted to be made to include also the
03:09conditioned innovativeness, and I am referring, in particular, to that six-year limit, beyond
03:15which, regardless of the goodness of the success of the research, we can no longer count in
03:22us, but above all the patients, on the possibility of accessing the innovative fund.
03:27This is not right because it is not right and above all it makes no sense, there is no
03:32scientific rationale in setting a time limit to research.
03:37Progressive research must move forward, and therefore it is not clear why it must reward
03:43what is innovative within the first six years and then arbitrarily, after six years, this
03:50should not happen.
03:51So, we hope that this norm will be expectably either abolished or at least extended until
03:58ten years, so that there is also an incentive, even for highly innovative companies like
04:03ours, to invest in clinical research even beyond the sixth year, with respect to the
04:09life of the product itself.
Comments